Neuphoria Therapeutics Inc. cotiza a 3.39 USD y tiene una capitalización bursátil de $18M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic a…
| Periodo | 2026-09 | 2026-05 | 2026-02 | 2025-11 |
|---|---|---|---|---|
| Real | $0.26 | $-0.09 | $0.41 | $-4.41 |
| Estimado | $-0.56 | $-0.56 | $-0.56 | $-1.31 |
| Sorpresa | +146.4% | +83.9% | +173.2% | -236.6% |
| Métrica | NEUP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1401.1% | -38.6% | -1362.5% |
| Net Margin | -1145.7% | -33.6% | -1112.1% |
| FCF Margin | — | -13.9% | — |
| ROE | -54.7% | -40.4% | -14.3% |
| ROA | -46.9% | -32.0% | -14.9% |
| Current Ratio | 27.85 | 2.84 | +25.01 |
| Debt / Equity | — | 0.28 | — |